MA50634A - Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam - Google Patents
Compositions pharmaceutiques à libération prolongée comportant du lévétiracétamInfo
- Publication number
- MA50634A MA50634A MA050634A MA50634A MA50634A MA 50634 A MA50634 A MA 50634A MA 050634 A MA050634 A MA 050634A MA 50634 A MA50634 A MA 50634A MA 50634 A MA50634 A MA 50634A
- Authority
- MA
- Morocco
- Prior art keywords
- sustained
- pharmaceutical compositions
- compositions containing
- release pharmaceutical
- containing levetiracetam
- Prior art date
Links
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 title 1
- 229960004002 levetiracetam Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562165812P | 2015-05-22 | 2015-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50634A true MA50634A (fr) | 2021-04-28 |
Family
ID=61223552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050634A MA50634A (fr) | 2015-05-22 | 2016-05-20 | Compositions pharmaceutiques à libération prolongée comportant du lévétiracétam |
Country Status (4)
| Country | Link |
|---|---|
| EP (2) | EP3297611B1 (fr) |
| DK (1) | DK3297611T3 (fr) |
| ES (1) | ES2747993T3 (fr) |
| MA (1) | MA50634A (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4504176A1 (fr) * | 2022-04-01 | 2025-02-12 | Agenebio, Inc. | Méthodes de prévention ou de ralentissement de la progression d'un déclin ou d'un trouble cognitif chez des sujets présentant une performance cognitive normale |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ540288A (en) | 2002-11-22 | 2009-06-26 | Univ Johns Hopkins | Target for therapy of cognitive impairment |
| EP2682481A3 (fr) | 2005-08-03 | 2014-09-17 | The Johns-Hopkins University | Procédés de caractérisation et de traitement de la déficience cognitive lors du vieillissement et de la maladie |
| US20080014264A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
| WO2008062446A2 (fr) * | 2006-09-14 | 2008-05-29 | Alembic Limited | Composition de lévétiracétam à libération prolongée n'impliquant pas d'effets indésirables en présence d'aliments |
| ES2865504T3 (es) * | 2008-10-16 | 2021-10-15 | Univ Johns Hopkins | Procedimientos y composiciones para la mejora de la función cognitiva |
| KR20120055313A (ko) * | 2010-11-23 | 2012-05-31 | 주식회사 바이오파마티스 | 레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법 |
| DE102011103270A1 (de) * | 2011-05-26 | 2012-11-29 | Stada Arzneimittel Ag | Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten |
| JP6433482B2 (ja) * | 2013-03-15 | 2018-12-05 | エージンバイオ, インコーポレイテッド | 認知機能を改善するための方法および組成物 |
-
2016
- 2016-05-20 MA MA050634A patent/MA50634A/fr unknown
- 2016-05-20 EP EP16728462.9A patent/EP3297611B1/fr active Active
- 2016-05-20 DK DK16728462.9T patent/DK3297611T3/da active
- 2016-05-20 ES ES16728462T patent/ES2747993T3/es active Active
- 2016-05-20 EP EP19175798.8A patent/EP3590506A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3590506A1 (fr) | 2020-01-08 |
| ES2747993T3 (es) | 2020-03-12 |
| ES2747993T8 (es) | 2021-03-30 |
| EP3297611B1 (fr) | 2019-07-03 |
| EP3297611A1 (fr) | 2018-03-28 |
| DK3297611T3 (da) | 2019-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3493799A4 (fr) | Composition pharmaceutique decannabis | |
| DK3529248T3 (da) | Farmaceutiske sammensætninger | |
| DK3655038T3 (da) | Farmaceutisk sammensætning | |
| DK3256138T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam | |
| EP3493798A4 (fr) | Composition pharmaceutique decannabis | |
| DK3253382T3 (da) | Farmaceutiske sammensætninger til kombinationsterapi | |
| EP3391459A4 (fr) | Filtres à retard temporel | |
| EP3310439A4 (fr) | Compositions pharmaceutiques pour des applications anesthésiologiques | |
| MA44212A (fr) | Prégabaline à libération prolongée contrôlée | |
| EP3603642A4 (fr) | Préparation pharmaceutique | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| EP3272362A4 (fr) | Composition pharmaceutique à libération prolongée | |
| MA44079A (fr) | Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine | |
| DK3908321T3 (da) | Farmaceutisk sammensætning | |
| DK3728220T3 (da) | Farmaceutiske forbindelser | |
| DK3313370T3 (da) | Oftalmologisk farmaceutisk sammensætning | |
| SMT202400478T1 (it) | Composizione farmaceutica | |
| EP3646863A4 (fr) | Composition pharmaceutique | |
| EP3524250A4 (fr) | Composition pharmaceutique | |
| DK3288933T3 (da) | Oxindolforbindelser og farmaceutiske sammensætninger deraf | |
| DK3302483T3 (da) | Farmaceutiske sammensætninger og anvendelse deraf | |
| EP3705122A4 (fr) | Composition pharmaceutique à libération prolongée | |
| PT3949952T (pt) | Composição farmacêutica | |
| EP3638211A4 (fr) | Compositions pharmaceutiques à libération prolongée retardée |